Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
Phase 3 , open-label, randomized study to evaluate the safety and efficacy of the
Lilly/Alkermes inhaled insulin system compared to injected insulin in type 1 and type 2
diabetes patients with asthma or COPD. Patients will be treated for 12 months with a 2 month
follow up period.